An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)

Trial Profile

An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs Inclisiran (Primary) ; Evolocumab
  • Indications Atherosclerosis; Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms ORION-3
  • Sponsors The Medicines Company
  • Most Recent Events

    • 12 Jan 2017 New trial record
    • 08 Jan 2017 According to the Medicines company media release, subject to discussions with regulatory authorities, this study will be conducted in parallel with the Phase 3 development program for inclisiran. The estimated study period of this trial is four years, or until inclisiran receives regulatory approval, whichever occurs first.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top